IBSRELA achieved 73% revenue growth in 2025, driven by a first-in-class mechanism that addresses the 77% of IBS-C patients who remain symptomatic on secretagogues. Management successfully executed a patient-first strategy for XPHOZAH, maintaining access for all appropriate patients despite the loss of Medicare Part D reimbursement. The company strengthened its intellectual property moat with a new formulation patent for IBSRELA and XPHOZAH that extends protection until 2042. Operational performance ...